Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The objective of this study was to evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) as maintenance monotherapy for patients with generalized anxiety disorder (GAD). Time-to-event (anxiety symptom recurrence; maximum 52 weeks) multicenter, randomized-withdrawal, parallel-group, double-blind, placebo-controlled study of quetiapine XR (50-300 mg/day) following open-label run-in (4-8 weeks) and open-label stabilization (≥ 12 weeks). Primary variable: time from randomization to anxiety event. Secondary variables included: Hamilton Anxiety Rating Scale (HAM-A) total, HAM-A psychic/somatic anxiety factors, Clinical Global Impression-Severity of Illness (CGI-S), and Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) scores; adverse events (AE) reporting. Four hundred and thirty-two patients, stabilized on quetiapine XR, were randomized to continue quetiapine XR (N=216) or switch to placebo (N=216). Risk of anxiety symptom recurrence was significantly reduced by 81% for quetiapine XR versus placebo: hazard ratio=0.19 (95% confidence interval 0.12-0.31; P<0.001). Fewer patients receiving quetiapine XR (N=22, 10.2%) than placebo (N=84, 38.9%) experienced anxiety symptom recurrence. Significant differences were observed between quetiapine XR and placebo in: HAM-A total, psychic/somatic, CGI-S (all P<0.001) and Q-LES-Q (P<0.05) scores. AEs (>10%) during open-label treatment were dry mouth, sedation, somnolence, dizziness, fatigue, and constipation. During randomized treatment, the most common AEs for quetiapine XR were headache and nasopharyngitis. Quetiapine XR monotherapy reduced the risk of anxiety symptom recurrence in patients with GAD stabilized on quetiapine XR, with tolerability results consistent with the known profile of quetiapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 1×
“The diagnosis, course, and treatment of GAD is frequently complicated by the presence of other comorbid psychiatric disorders and/or medical conditions, such as MDD, other anxiety disorders, cardiovascular, gastrointestinal, and respiratory disease (Wittchen et al., 1994).”
BackgroundSareen, J., Cox, B. J., Afifi, T. O., de Graaf, R., Asmundson, G. J. G., ten Have, M., & Stein, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1249 · Cited by 824
Risk factors for suicidality in Europe: Results from the ESEMED study
Bernal, M., Haro, J. M., Bernert, S., Brugha, T., de Graaf, R., Bruffaerts, R., Lépine, J. P., de Girolamo, G., Vilagut, G., Gasquet, I., et al. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.09.018 · Cited by 565 · cited 2×
“GAD is associated with an increased risk of suicide or suicide attempts (Sareen et al., 2005; Bernal et al., 2007) and a marked degree of impairment equivalent to that observed in patients with major depressive disorder (MDD) (Kessler et al., 1999).”
ResultHuman and economic burden of generalized anxiety disorder
Hoffman, D. L., Dukes, E. M., & Wittchen, H.-U. (2008) · Depression and Anxiety · doi:10.1002/da.20257 · Cited by 438
Phenomenology and Course of Generalised Anxiety Disorder
Yonkers, K. A., Warshaw, M. G., Massion, A. O., & Keller, M. B. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.3.308 · Cited by 242 · cited 2×
“…the finding that quetiapine XR is effective in reducing the risk of recurrence of anxiety symptoms is important when placed in the context of the chronic and fluctuating nature of the illness (Yonkers et al., 1996; Wittchen et al., 2000), and the high levels of relapse (Andrews et al., 2000).”
Background(2000) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862000000400006 · Cited by 195
Impairment and quality of life in individuals with generalized anxiety disorder
Henning, E. R., Turk, C. L., Mennin, D. S., Fresco, D. M., & Heimberg, R. G. (2007) · Depression and Anxiety · doi:10.1002/da.20249 · Cited by 189 · cited 2×
“The persistent and unremitting symptoms of generalized anxiety disorder (GAD) mean that the burden of illness is substantial and patients often suffer from diminished social functioning and quality of life (Henning et al., 2007).”
BackgroundAripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder
Hoge, E. A., Worthington, J. J., Kaufman, R. E., Delong, H. R., Pollack, M. H., & Simon, N. M. (2008) · CNS Spectrums · doi:10.1017/s109285290001676x · Cited by 58 · cited 1×
“…efficacy in terms of improvement of HAM-A total score for risperidone (Brawman-Mintzer et al., 2005; Simon et al., 2006), quetiapine (Katzman et al., 2008), and olanzapine (Pollack et al., 2006), and reduction in CGI-S score by olanzapine (Pollack et al., 2006) and aripiprazole (Hoge et al., 2008).”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Pregabalin [628] and quetiapine XR [629] have also demonstrated”
BackgroundSelf-citationDhir, A., Yossatorn, Y., Kaur, P., & Chen, S. (2018) · International Journal of Information Management · doi:10.1016/j.ijinfomgt.2018.01.012 · Cited by 1,033
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…advantage for staying on active medication (agomelatine, duloxetine, escitalopram, paroxetine, pregabalin, quetiapine, venlafaxine, vortioxetine), when compared with switching to placebo, for periods of between 6–18 months (Baldwin et al., 2011b, 2012; Katzman et al., 2011; Rickels et al., 2010).”
BackgroundMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Metadata
- Authors
- Katzman, M. A., Brawman-Mintzer, O., Reyes, E. B., Olausson, B., Liu, S., & Eriksson, H.
- Venue
- International Clinical Psychopharmacology
- Published
- 2011-01
- Volume
- 26
- Issue
- 1
- Pages
- 11-24
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1993810555
- Cited by
- 75
- References
- 8
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. https://app.cochat.ai/papers/10.1097/yic.0b013e32833e34d9
- The paper
- Katzman, M. A., Brawman-Mintzer, O., Reyes, E. B., Olausson, B., Liu, S., & Eriksson, H. (2011). Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32833e34d9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.